In AML, Smith et al. reported oncogenic FLT3 activation could inactivate PP2A via decreasing PP2A-A and PP2A-B expressions in AML cell lines and primary human AML blasts [22]. This evidence concerns the gene PPP2R1A and acute myeloid leukemia.